Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega 3 PUFA for Age-related Cognitive Decline
NCT01953705Phase 2Unknown
- Sponsor
- Oregon Health & Science University
- Start
- May 2014
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in age-related cognitive decline, Alzheimer's disease (AD) and vascular dementia comparing Omega 3 PUFA with Placebo (2 arms). Primary endpoint: Total cerebral white matter hyperintensity volume at 3 years. Status: unknown.
02
Drugs
omega-3-acid triglycerides
03
Conditions
age-related cognitive declineAlzheimer's disease (AD)vascular dementia
Beyond the preview
Go deeper on NCT01953705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01953705.